Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas

What Was Tested

This clinical trial paper looks at Octreotide and Somatostatin.

No previous studies have been undertaken to evaluate the SSTR and DR profile related with the gsp status in somatotropinomas.

To determine if (1) gsp status is correlated with response to octreotide LAR (LAR) and tumor expression patterns of SSTR1-5 and DR1-5 and (2) cAMP level can directly modulate SSTR and DR mRNA levels.

Quantitative real-time PCR was used to determine SSTR and DR tumor expression.

Why It Was Studied

It has been reported in some series that gsp+ somatotropinomas are more sensitive to somatostatin analogues (SA) and dopamine's actions which may be related to their somatostatin receptor (SSTR) and dopamine receptor (DR) profile.

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

Conventional PCR and sequencing were used to identify gsp+ tumors.

Primary pituitary cell cultures of primates were used to study whether SSTR and DR expression is regulated by forskolin.

What Was Measured

The subject headings attached to it are Adenoma, Cell Culture Techniques, Chromogranins, Colforsin, GTP-Binding Protein alpha Subunits, Gs, Gene Expression Regulation, Neoplastic and Octreotide.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Neuroendocrinology), a journal based in Switzerland.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.